Dr. Ornstein is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
9500 Euclid Ave
# CA-60
Cleveland, OH 44195Phone+1 216-445-6592
Education & Training
Stony Brook University Health Sciences Center School of MedicineClass of 2011
Certifications & Licensure
OH State Medical License 2013 - 2026- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Medical Professionals' Perceptions of and Experiences With Terminally Ill Orthodox Jewish Patients.Moshe C Ornstein, David Harris
The American Journal of Hospice & Palliative Care. 2025-01-04 - Phase II Trial of Intermittent Therapy in Patients with Metastatic Renal Cell Carcinoma Treated with Front-line Ipilimumab and Nivolumab.Moshe C Ornstein, Laeth George, Wei Wei, C Marcela Diaz-Montero, Pat Rayman
Clinical Genitourinary Cancer. 2024-12-01 - 2 citationsTreatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohor...Michael B Atkins, Opeyemi A Jegede, Naomi B Haas, David F Mcdermott, Mehmet A Bilen
Journal for Immunotherapy of Cancer. 2024-04-11
Press Mentions
Prostate Cancer Screening Guidelines May Fail to Address Racial Disparity: StudyNovember 10th, 2022- More Benefit with Taxane for Aggressive Metastatic Prostate CancerApril 12th, 2021
Metastatic Non-Clear Cell Renal Cancer Patients Have Positive Response to ImmunotherapyApril 12th, 2019- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
